Theranovir

#Health / Well-being #Therapeutics

• Drug development
• Antibody
• Cancer
• Immunotherapy
• Tumor Agnostic Therapy
• Companion test
• Targeted therapy
• Obesity, HIV and Covid19

BACKGROUND

Young and multidisciplinary French start-up, THERANOVIR develops immunotherapeutic innovative antibodies for three diversified and interconnected pathologies:

• Cancer relapse and therapy resistance with new companion test in favor of agnostic indication.
• Obesity as alternative solution for bariatric surgery.
• Repurposing strategy for infectious diseases such as HIV reservoir and Covid19.

This project is the result of academic research

DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY

The main axe of THERANOVIR is oncology. THERANOVIR is developing innovative therapeutic monoclonal antibodies targeting both tumor cells (stem and non-stem) and cells of the microenvironment in combination with a companion immunohistological test. Being in the preclinical phases, candidates under development will be proposed in combination in response to therapeutic failures of checkpoint inhibitors and / or anti-angiogenesis in combination with chemotherapy.

At the same time, THERANOVIR is progressing in the development of immunotherapeutic antibodies targeting obesity.

COLLABORATIONS SOUGHT

THERANOVIR is currently looking for funding to progress in the preclinical development in order to enter the regulatory and the clinical phases.

We are interested to tie partnerships with big pharma to ensure the development of our products in clinical phases and beyond.

• Further information

  The IP is protected by a family of 2 patents covering Europe, US and Asia that THERANOVIR exploits via a global and exclusive license from INSERM Transfert.

  STRENGTHS

  Cohesive and complementary skilled team, 100% of employees are PhD holders. THERANOVIR is supported by an advisory board represented by KOL experts.

  THERANOVIR is surrounded by an ecosystem supporting innovations and specially startup in Health-Tech represented by Genopole, Medicen, Mabdesign, France Biotech, Bpifrance, Region Ile-de-France.

  INNOVATION ASSETS

  The target is a new complex of proteins expressed in many cancer types which allows us to propose an agnostic therapy.

  The offer is complete including companion test to identify if the treatment is effective on the patient and the therapy itself.

  The therapy is validated in vitro and in vivo recently and until today, there is no treatment targeting this protein complex in the pharmacopeia.